AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
ORLANDO, FLA. -- Rofecoxib was associated with an increase in mean systolic blood pressure, but celecoxib was not, in a randomized trial of the cyclooxygenase-2 inhibitors in arthritic patients with treated hypertension.
Celecoxib-treated patients were also less likely to develop clinically significant edema. And when they did develop edema, blood pressure rose substantially less than in edematous rofecoxib-treated patients, Dr. William B. White said at the annual meeting of the American College of Cardiology.
An estimated 12 million Americans with hypertension have comorbid arthritis and are therefore at risk for developing renal side effects if they take antihypertensive drugs along with conventional nonselective NSAIDs. These are patients likely to be using cyclooxygenase-2 (COX-2) inhibitors.
If rofecoxib tends to worsen blood pressure control in those patients and celecoxib does not, that's a practical consideration, according to Dr. White, who serves on the speakers' bureau for Merck & Co., manufacturer of the drug, ...